A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

NCT ID: NCT05337657

Last Updated: 2022-04-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-02
• Study Completion Date: 2024-02-01

Brief Summary

GB491-005 is a multicenter, open-label, phase Ib Clinical Trial study to evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GB491 in combination with Letrozole in Previously Untreated Patients with HR-positive, HER2-negative Advanced Breast Cancer

Conditions

Advanced Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

GB491+Letrozole

Group Type: EXPERIMENTAL

GB491+Letrozole

Intervention Type: DRUG

Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart

Interventions

GB491+Letrozole

Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Females of 18 years of age or older at study screening

2. Histologically or cytologically confirmed locally advanced or advanced metastatic breast cancer that is not amenable to curative surgical resection or radiation therapy

3. The subject has been diagnosed with ER-positive breast cancer in the local laboratory

4. The subject has HER2-negative breast cancer in the local laboratory

5. Menopausal status is not limited (including Premenopausal/perimenopausal/postmenopausal state)

6. No previous systemic anti-tumor treatment for locally advanced or metastatic breast cancer;

7. According to RECIST V1.1, the patient has at least one measurable lesion that has not been irradiated by radiotherapy and can be evaluated by CT/MRI; If only bone metastases are present, there must be at least one osteolytic bone lesion that can be evaluated by CT/MRI

8. ECOG performance status of 0 or 1

9. Adequate organ and marrow function.

10. The subject of childbearing potential must use one highly effective birth control method from the total duration of the study and 6 months after the last dose of study intervention.

11. Provide informed consent

Exclusion Criteria

1. Previous treatment with CDK4/6 inhibitors

2. Subjects with known hypersensitivity to any component of GB491 or Letrozole

3. Patients with disease progression or recurrence during or within 1 year after completion of previous endocrine neoadjuvant or adjuvant therapy

4. Known active, uncontrolled, or symptomatic central nervous system metastasis, carcinomatous meningitis, or clinically manifested leptomeningeal disease, cerebral edema, spinal compression or/and tumor progressive growth

5. Visceral crisis

6. Patients with skin lesion only and radiographically non-measurable at baseline

7. Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy, excluding alopecia

8. Major surgical procedure within 4 weeks of the first dose of study treatment or an anticipated need for major surgery, chemotherapy, radiotherapy, any other investigational drug or other anti-cancer therapy during the study

9. Patients who have been on bisphosphonates and denosumab therapy at a stable dose for less than 14 days prior to randomization

10. Patients who have received limited field radiotherapy in 2 weeks or extended field radiotherapy in 4 weeks before randomization or radiation with more than 30% of the bone marrow

11. Subjects use drugs or fruits containing strong inducers or inhibitors of CYP3A4/5, or drugs with narrow therapeutic window that are mainly metabolized by CYP3A4/5 in 14 days before randomization

12. Patients with long-term systematic use of corticosteroids

13. Any severe and/or uncontrollable medical conditions

14. Patients with severely impaired lung function

15. Known history of HIV infection or history of HIV seropositivity

16. Resting QTcF > 480 msec or there is a medical history of QTcF prolongation

17. Subjects have significant hepatic disease

18. Coagulation abnormalities

19. Refractory nausea and vomiting, inability to swallow the formulated product, or other disease or clinical status would preclude adequate absorption, distribution, metabolism, or excretion of GB491

20. Previous allogeneic bone marrow transplant

21. Inflammatory breast cancer;

22. Subjects with a history of other primary malignancies, except for non-melanoma skin cancer and cervical cancer in situ disease-free status ≥ 3 years

23. Lactating women

24. Unlikely to comply with study procedures, restrictions, and requirements

25. Judgment by the investigator that the patient should not participate into the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Genor Biopharma Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xichun Hu, PhD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Jian Zhang, PhD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Shawn Yu

Role: CONTACT

shawn.yu@genorbio.com

021-60751991

Facility Contacts

Xichun Hu, PhD

Role: primary

xchun2009@hotmail.com

13816110335

Jian Zhang, PhD

Role: backup

syner2000@163.com

18017312991

Other Identifiers

GB491-005

Identifier Type: -

Identifier Source: org_study_id